Core Viewpoint - Inspire Medical Systems, Inc. is recognized for its innovative sleep apnea treatment solutions, particularly the Inspire therapy device, while facing a class action lawsuit that may impact investor sentiment [1][2][5] Company Overview - Inspire Medical Systems specializes in medical solutions for sleep apnea, particularly through its implantable Inspire therapy device [1] - The company's current stock price is $89.87, reflecting a recent increase of 7.92% or $6.60 [3][5] - The market capitalization of Inspire Medical Systems is approximately $2.66 billion, indicating its significant presence in the market [3] Analyst Ratings - Stifel Nicolaus has upgraded Inspire Medical Systems to a "Buy" rating with a price target of $110, suggesting a potential increase of 22.4% from the current stock price [1][5] Legal Challenges - The company is currently involved in a class action lawsuit led by the Schall Law Firm, alleging violations of the Securities Exchange Act of 1934, affecting investors who purchased INSP securities between August 6, 2024, and August 4, 2025 [2][5] - Shareholders who have experienced losses are encouraged to contact the law firm before January 5, 2026 [2] Trading Activity - The trading volume for INSP on the NYSE is 1,073,158 shares, indicating active investor interest despite ongoing legal challenges [4][5] - The stock has fluctuated between $83.37 and $90.55 today, with a yearly high of $216.01 and a low of $70.77 [3]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Chijet Motor Company, Inc. (CJET) is up 40% at $2.67 - JX Luxventure Group Inc. (JXG) is up 19% at $4.12 - Inspire Medical Systems, Inc. (INSP) is up 15% at $103.50 - Epsium Enterprise Limited (EPSM) is up 15% at $4.14 - Oscar Health, Inc. (OSCR) is up 12% at $15.13 - Green Dot Corporation (GDOT) is up 11% at $13.21 - Butterfly Network, Inc. (BFLY) is up 6% at $2.82 - Cullinan Therapeutics, Inc. (CGEM) is up 5% at $10.00 - Vir Biotechnology, Inc. (VIR) is up 5% at $5.99 - Nvni Group Limited (NVNI) is up 5% at $3.17 [3] Premarket Losers - Clearside Biomedical, Inc. (CLSD) is down 69% at $0.82 - Twin Hospitality Group Inc. (TWNP) is down 20% at $2.84 - Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is down 15% at $1.35 - Mobile-Network Solutions (MNDR) is down 12% at $4.16 - Waldencast plc (WALD) is down 10% at $2.75 - authID Inc. (AUID) is down 9% at $1.21 - EZGO Technologies Ltd. (EZGO) is down 6% at $1.98 - SciSparc Ltd. (SPRC) is down 5% at $2.34 - Twin Vee Powercats Co. (VEEE) is down 5% at $1.70 - Agape ATP Corporation (ATPC) is down 5% at $1.22 [4]

INSPIRE NOTICE: Inspire Medical Systems, Inc. (INSP) Faces Securities Fraud Allegations after Stock Drops 32%, Investors Urged to Contact BFA LawNovember 24, 2025 6:08 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 24, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after ...

Core Viewpoint - Inspire Medical Systems is facing a class action lawsuit due to alleged violations of federal securities laws, including making false statements about the demand and launch of its Inspire V device [6][9]. Group 1: Legal Action and Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems and has set a deadline of January 5, 2026, for investors to seek the role of lead plaintiff in the class action lawsuit [3]. - Investors who suffered losses between August 6, 2024, and August 4, 2025, are encouraged to contact the law firm to discuss their legal rights [2][3]. Group 2: Company Performance and Issues - On August 4, 2025, Inspire Medical announced significant setbacks in the launch of its Inspire V device, citing delays in training and onboarding at treatment centers [7]. - The company faced billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, 2025, preventing centers from billing for procedures [8]. - Inspire Medical reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [9]. - Following these announcements, Inspire's stock price plummeted over 32% in one day, resulting in a loss of approximately $1.2 billion in market capitalization [9].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop attributed to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption and weak demand due to excess inventory of older devices [5][6]. - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. Stock Performance - Following the announcement of the delayed launch, Inspire's stock price fell by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Rosen Law Firm is encouraging investors of Inspire Medical Systems, Inc. to secure legal counsel before the January 5, 2026 deadline for a class action lawsuit related to the company's stock performance during the specified class period [1][3]. Group 1: Class Action Details - The class period for the Inspire Medical Systems, Inc. stock is from August 6, 2024, to August 4, 2025, inclusive [1]. - Investors who purchased common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by January 5, 2026 [3]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Inspire Medical Systems misrepresented key facts about its Inspire V sleep apnea device, including market demand and readiness for launch, leading to misleading statements that inflated investor confidence [5].

Accessibility StatementSkip Navigation BENSALEM, Pa., Nov. 21, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Inspire Medical Systems, Inc. ("Inspire" or the "Company") (NYSE: INSP) 21% more press release views with Request a Demo Also from this source IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INSPIRE MEDICAL SYSTEMS, INC. (INSP), CONTACT THE LAW OFFICES OF HOWARD G. SMIT ...

Core Viewpoint - Inspire Medical Systems is facing legal scrutiny due to allegations of misleading investors regarding the demand and launch of its Inspire V device, leading to significant financial losses for investors [3][4][5]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical and has set a deadline of January 5, 2026, for investors to seek the role of lead plaintiff in a federal securities class action [1][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2]. Group 2: Financial Impact - On August 4, 2025, Inspire Medical announced delays in the launch of the Inspire V device due to training and onboarding issues at treatment centers, as well as billing challenges with Medicare [4]. - Following the announcement of these setbacks, Inspire Medical's stock price plummeted over 32%, from $129.95 to $87.91 per share, resulting in a loss of approximately $1.2 billion in market capitalization [5]. - The company also reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [5].

Core Viewpoint - A class action securities lawsuit has been filed against Inspire Medical Systems, Inc. due to alleged securities fraud affecting investors between August 6, 2024, and August 4, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that the launch of Inspire Medical's new product, Inspire V, was unsuccessful due to poor demand and excess inventory at treatment centers, contradicting the company's assurances of a successful launch [3]. - Defendants allegedly failed to complete essential tasks for the product launch, including training for treatment center customers, setting up IT systems, and ensuring proper Medicare reimbursement [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption [5][6]. - The company faced weak demand for Inspire V as many customers had excess inventory of older devices [6]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price plummeted by $42.04 per share, or more than 32%, from $129.95 to $87.91 between August 4 and August 5, 2025 [8].